Cargando…

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Hsing-Wei, Liu, Chien-Ying, Chen, Hsiu-Fang, Chang, Chun-Chu, Chen, Shu-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199281/
https://www.ncbi.nlm.nih.gov/pubmed/34073174
http://dx.doi.org/10.3390/ijerph18115677
_version_ 1783707339677761536
author Hung, Hsing-Wei
Liu, Chien-Ying
Chen, Hsiu-Fang
Chang, Chun-Chu
Chen, Shu-Ching
author_facet Hung, Hsing-Wei
Liu, Chien-Ying
Chen, Hsiu-Fang
Chang, Chun-Chu
Chen, Shu-Ching
author_sort Hung, Hsing-Wei
collection PubMed
description Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL.
format Online
Article
Text
id pubmed-8199281
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81992812021-06-14 Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy Hung, Hsing-Wei Liu, Chien-Ying Chen, Hsiu-Fang Chang, Chun-Chu Chen, Shu-Ching Int J Environ Res Public Health Article Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL. MDPI 2021-05-26 /pmc/articles/PMC8199281/ /pubmed/34073174 http://dx.doi.org/10.3390/ijerph18115677 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hung, Hsing-Wei
Liu, Chien-Ying
Chen, Hsiu-Fang
Chang, Chun-Chu
Chen, Shu-Ching
Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
title Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
title_full Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
title_fullStr Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
title_full_unstemmed Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
title_short Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
title_sort impact of chemotherapy-induced peripheral neuropathy on quality of life in patients with advanced lung cancer receiving platinum-based chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199281/
https://www.ncbi.nlm.nih.gov/pubmed/34073174
http://dx.doi.org/10.3390/ijerph18115677
work_keys_str_mv AT hunghsingwei impactofchemotherapyinducedperipheralneuropathyonqualityoflifeinpatientswithadvancedlungcancerreceivingplatinumbasedchemotherapy
AT liuchienying impactofchemotherapyinducedperipheralneuropathyonqualityoflifeinpatientswithadvancedlungcancerreceivingplatinumbasedchemotherapy
AT chenhsiufang impactofchemotherapyinducedperipheralneuropathyonqualityoflifeinpatientswithadvancedlungcancerreceivingplatinumbasedchemotherapy
AT changchunchu impactofchemotherapyinducedperipheralneuropathyonqualityoflifeinpatientswithadvancedlungcancerreceivingplatinumbasedchemotherapy
AT chenshuching impactofchemotherapyinducedperipheralneuropathyonqualityoflifeinpatientswithadvancedlungcancerreceivingplatinumbasedchemotherapy